

Title (en)
SOLUBLE DRUG EXTENDED RELEASE SYSTEM

Title (de)
SYSTEM FÜR DIE VERZÖGERTE FREISETZUNG VON LÖSLICHEN MEDIKAMENTEN

Title (fr)
SYSTEME DE LIBERATION PROLONGEE DE MEDICAMENTS SOLUBLES

Publication
EP 1443901 A4 20100616 (EN)

Application
EP 02782303 A 20021112

Priority
• US 0236681 W 20021112
• US 787701 A 20011113

Abstract (en)
[origin: WO03041656A2] This invention relates to novel oral sustained-release formulations for delivery of an active agent (e.g., a drug), especially a highly water soluble drug. More particularly, this invention relates to novel formulations comprising a micelle-forming drug having a charge and at least one polymer having an opposite charge. Methods of using the novel formulations are also provided.

IPC 1-7
A61K 9/00; **A61K 9/127**; **A61K 9/52**; **A61K 9/22**; **A61K 9/14**; **A61K 31/78**

IPC 8 full level
A61K 9/107 (2006.01); **A61K 9/20** (2006.01); **A61K 9/22** (2006.01); **A61K 9/52** (2006.01); **A61K 47/26** (2006.01); **A61K 47/30** (2006.01); **A61K 47/32** (2006.01); **A61K 47/34** (2006.01); **A61K 47/36** (2006.01)

CPC (source: EP KR)
A61K 9/00 (2013.01 - KR); **A61K 9/20** (2013.01 - KR); **A61K 9/2013** (2013.01 - EP); **A61K 9/2018** (2013.01 - EP); **A61K 9/2027** (2013.01 - EP); **A61K 9/2031** (2013.01 - EP); **A61K 9/2054** (2013.01 - EP); **A61K 9/28** (2013.01 - KR)

Citation (search report)
• [X] WO 9706787 A2 19970227 - DYER ALISON MARGARET [ZA], et al
• [X] WO 0015198 A1 20000323 - RANBAXY LAB LTD [IN], et al
• [X] GB 1263392 A 19720209 - AMERICAN HOME PROD [US]
• [X] TOLIAT T ET AL: "Controlled release (CR) tablet formulation of diltiazem HCL using different polymers as retardant substances", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 14, no. 11 SUPPL., November 1997 (1997-11-01), & ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS; BOSTON, MASSACHUSETTS, USA; NOVEMBER 2-6, 1997, pages S598, XP008121997, ISSN: 0724-8741
• [X] KRISTMUNDSOTTIR T ET AL: "CHITOSAN MATRIX TABLETS: THE INFLUENCE OF EXCIPIENTS ON DRUG RELEASE", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US LNKD- DOI:10.3109/03639049509069249, vol. 21, no. 13, 1 January 1995 (1995-01-01), pages 1591 - 1598, XP009026687, ISSN: 0363-9045
• See references of WO 03041656A2

Citation (examination)
• EP 0661045 B1 20020703 - YAMANOUCHI PHARMA CO LTD [JP]
• MAGGI L ET AL: "Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 23, no. 4, 15 February 2002 (2002-02-15), pages 1113 - 1119, XP004348129, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(01)00223-X
• ATTWOOD D ET AL: "AGGREGATION OF ANTI DEPRESSANT DRUGS IN AQUEOUS SOLUTION", JOURNAL OF PHARMACY AND PHARMACOLOGY, LONDON; GB, vol. 30, no. 3, 1 January 1978 (1978-01-01), pages 176 - 180, XP008122056, ISSN: 0022-3573

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

Designated extension state (EPC)
AL LT LV MK RO SI

DOCDB simple family (publication)
WO 03041656 A2 20030522; **WO 03041656 A3 20031023**; AU 2002348279 B2 20080124; AU 2002348279 C1 20080904; CA 2466657 A1 20030522; CA 2466657 C 20110201; CN 100534531 C 20090902; CN 1612726 A 20050504; EP 1443901 A2 20040811; EP 1443901 A4 20100616; JP 2005508995 A 20050407; JP 2011068700 A 20110407; JP 4882200 B2 20120222; JP 4894958 B2 20120314; KR 101016619 B1 20110223; KR 101132969 B1 20120409; KR 20050044424 A 20050512; KR 20100123779 A 20101124; MX PA04004544 A 20050331; PL 374280 A1 20051003; RU 2004117848 A 20050527; RU 2322263 C2 20080420

DOCDB simple family (application)
US 0236681 W 20021112; AU 2002348279 A 20021112; CA 2466657 A 20021112; CN 02827035 A 20021112; EP 02782303 A 20021112; JP 2003543543 A 20021112; JP 2011004215 A 20110112; KR 20047007206 A 20021112; KR 20107024523 A 20021112; MX PA04004544 A 20021112; PL 37428002 A 20021112; RU 2004117848 A 20021112